Allakos Inc

Founded in 2012, Allakos Inc is a US-based healthcare company and provider of specialised healthcare. The company offers a wide variety of clinical-stage medical research services across the US, including the development of therapeutic antibodies for use in the treatment of allergic, inflammatory and proliferative diseases. It is primarily focussed on helping patients with eosinophilic gastrointestinal diseases, which is a group of chronic inflammatory diseases that can be difficult to diagnose, but which can have a serious impact of the lives of suffers. Allakos has been based in Redwood City, California since its foundation. The company announced its Initial Public Offering in July 2018 and trades its stock on the NASDAQ GS under the ticker ALLK. The ALLK price chart showed a 52-week range of $41.61 to $139.99 as of November 2020, with a share price of $105.36. Allakos Inc is currently involved in clinical trials for Lirentelimab, a therapeutic treatment that is suitable for conditions such as Eosinophilic Gastritis and Eosinophilic Duodenitis, as well as other diseases of the skin and eye, such as chronic urticaria and severe allergic conjunctivitis. Are you thinking of diversifying your investments with medical stocks? Start today by adding ALLK stock to your portfolio.